{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:38:52Z","timestamp":1774669132273,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.transci.2013.01.002","type":"journal-article","created":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T11:49:54Z","timestamp":1361188194000},"page":"271-272","source":"Crossref","is-referenced-by-count":4,"title":["Successful management of imatinib despite alopecia and nail necrosis"],"prefix":"10.1016","volume":"48","author":[{"given":"Ulku","family":"Ergene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demircan","family":"Ozbalci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2013.01.002_b0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00520-008-0536-8","article-title":"Skin and oral lesions associated to imatinib mesylate therapy","volume":"4","author":"Basso","year":"2009","journal-title":"Supp Care Can"},{"key":"10.1016\/j.transci.2013.01.002_b0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-0609.2004.00351.x","article-title":"Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib","volume":"74","author":"Breccia","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transci.2013.01.002_b0015","first-page":"228","article-title":"Imatinib mesylate and dermatology part 2: a review of cutaneous side effects of imatinib mesylate","volume":"3","author":"Scheinfeld","year":"2006","journal-title":"J Drugs Dermatol"},{"issue":"3\u20134","key":"10.1016\/j.transci.2013.01.002_b0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/13577140500349717","article-title":"Management of skin toxicity related to the use of imatinib mesylate (STI571, Glivec\u2122) for advanced stage gastrointestinal stromal tumours","volume":"9","author":"Scott","year":"2005","journal-title":"Sarcoma"},{"key":"10.1016\/j.transci.2013.01.002_b0025","doi-asserted-by":"crossref","unstructured":"Atallah E, Kantarjian H, Cortes J. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma 2007;(suppl. 3):S105\u201312.","DOI":"10.3816\/CLM.2007.s.010"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050213000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050213000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T12:32:14Z","timestamp":1539865934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050213000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1473050213000189"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2013.01.002","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}